正邦科技(002157.SZ):捐贈1000萬元支持新型冠狀病毒肺炎疫情防控
格隆匯2月3日丨正邦科技(002157.SZ)公佈,當前,國內新型冠狀病毒肺炎疫情日趨嚴峻,關乎全國人民的生命健康安全。公司密切關注疫情動態,在做好自身防控工作的同時,全力支持肺炎疫情防控工作,公司或下屬控股子公司累計捐贈1000萬元(其中,捐款500萬元人民幣;捐贈物資摺合人民幣約500萬元,主要為豬肉)用於防控新型冠狀病毒肺炎疫情。此次捐贈事項已經公司第六屆董事會第五次臨時會議審議通過,並授權公司經營管理層根據實際情況分期分批實施捐贈工作。根據《深圳證券交易所股票上市規則》等相關規定,此次捐贈無需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.